Overview

Entolimod, an Adjuvant for Vaccine Augmentation

Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this pilot study to evaluate the safety of low dose Entolimod in normal, healthy, non-patient normals. This clinical trial in 40 normal humans compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum with or without entolimod. Subjects will be randomized to: Td alone (n=15) and Td+ entolimod (n=25). The investigators expect that Td + entolimod will double the anti-TT and anti-diphtheria AB levels over Td alone.
Phase:
Early Phase 1
Details
Lead Sponsor:
Baylor College of Medicine
Treatments:
Vaccines